Inputs: momentum, trendVelocity
Momentum 0/100 with trend velocity 4/100 — trend is rolling over.
Prediction result · Ensemble engineUpdated 3:55 AM
RAPPRapport Therapeutics, Inc. stock price outlook
$25.05+3.47% since prev closeBearish
Rapport Therapeutics, Inc. (RAPP) is trading at $25.05, up 3.47% since the previous close and -3.39% over the past week. Price sits below its 50-day average by 31.75%, with price momentum at 0/100 and trend velocity at 4/100. Sentiment across 0 recent headlines reads mixed at 50/100. Volatility risk is elevated (100/100) and the stock is 10% of the way up its 52-week range. The weighted factor score lands at 27/100 — a bearish signal. Research only, not investment advice.
Universal leanmarket
RAPP
Rapport Therapeutics, Inc.
$25.05+3.47%
LEANSOFT bearish lean
WHY
- Rapport Therapeutics, Inc. (RAPP) is trading at $25.05, up 3.47% since the previous close and -3.39% over the past week. Price sits below its 50-day average by 31.75%, with price momentum at 0/100 and trend velocity at 4/100. Sentiment across 0 recent headlines reads mixed at 50/100. Volatility risk is elevated (100/100) and the stock is 10% of the way up its 52-week range. The weighted factor score lands at 27/100 — a bearish signal. Research only, not investment advice.
- Bear input: Momentum 0/100 with trend velocity 4/100 — trend is rolling over.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate on a reclaim of the session offer, catalyst relief, or model edge flipping bullish.
AI Signal
Bearish · Strong bearish edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
No relevant current headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment50/100
Price Momentum0/100
Trend Velocity4/100
Volatility Risk100/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
Rapport Therapeutics, Inc. (RAPP) is trading at $25.05, up 3.47% since the previous close and -3.39% over the past week. Price sits below its 50-day average by 31.75%, with price momentum at 0/100 and trend velocity at 4/100. Sentiment across 0 recent headlines reads mixed at 50/100. Volatility risk is elevated (100/100) and the stock is 10% of the way up its 52-week range. The weighted factor score lands at 27/100 — a bearish signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
38% of trees lean bearish on RAPP
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong bearish edgeBearish
Inputs: newsSentiment, dayChange
Sentiment 50/100 + price 3.5% are both mid-range.
Inputs: unusualVolume, dayChange
Volume read 17/100 with price drift 3.5% — no clear footprint.
Inputs: volatilityRisk, momentum
High volatility (100/100) without momentum support — wide path, more downside variance.
Inputs: pctOfRange, trendVelocity
Mid-range positioning — no edge from range alone.
Inputs: newsSentiment, weekChange
Sentiment 50/100 vs week change -3.4% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price -31.8% under 50d SMA with no momentum reclaim — downtrend intact.
Inputs: momentum, trendVelocity
Composite oscillator at 2 — washed-out zone, mean-reversion candidate.
Inputs: momentum, dayChange, vsSma50
Momentum 0/100 is not strong enough to confirm a breakout.
Inputs: newsSentiment, weekChange
News 50/100 and weekly change -3.4% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 17/100 is quiet and trend velocity is weak — move lacks sponsorship.
Inputs: volatilityRisk, pctOfRange, momentum
Very high volatility (100/100) with weak momentum is a rough setup for holders.
Inputs: pctOfRange, dayChange, weekChange
Price is at a range extreme, but the tape is not confirming the breakout.
Inputs: newsSentiment, momentum, weekChange
Sentiment 50/100 and momentum 0/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
Price is still under the 50d SMA and the trend has not reclaimed control.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 2 does not show a rebound edge.
Why the ensemble agrees
- Momentum 0/100 with trend velocity 4/100 — trend is rolling over.
- High volatility (100/100) without momentum support — wide path, more downside variance.
- Price -31.8% under 50d SMA with no momentum reclaim — downtrend intact.
Counter-trees
- Composite oscillator at 2 — washed-out zone, mean-reversion candidate.
Bull Case
- Composite oscillator at 2 — washed-out zone, mean-reversion candidate.
Bear Case
- Momentum 0/100 with trend velocity 4/100 — trend is rolling over.
- High volatility (100/100) without momentum support — wide path, more downside variance.
- Price -31.8% under 50d SMA with no momentum reclaim — downtrend intact.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
No current headlines passed the relevance filter. The watch panel above still shows the catalysts and risk factors being tracked.
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Market cap
- $1.20B
- 52-week range
- $52.93/$22.061
- Volume
- 926,646
- Avg volume
- 775,016
- Analyst 1-yr target
- $67.00
- Exchange
- NASDAQ-GM
Source: Nasdaq public quote data. Research only.
Insider trades
6 buys · 1 sells by RAPP insiders (SEC Form 4 filings)
- BUY Sanchez Ramiro Director · 2026-10-23$98K
- SELL Ceesay Abraham Chief Executive Officer · 2026-10-23$64K
- BUY Paul Steven M Director · 2026-10-22$974K
- BUY Maraganore John Director · 2026-10-22$217K
- BUY Young Wendy B. Director · 2026-10-22$100K
- BUY Silva Paul M Director · 2026-10-22$100K
Earnings Intelligence
Next
Nov 5, 2026
Estimate
$-1.21
Actual
$-1.19
- • Last report Aug 5, 2026 (Jun 2026): EPS $-1.19 vs $-0.93 expected, -27.96% surprise.
- • Beat estimates in 2 of the last 4 quarters.
- • Next report expected Nov 5, 2026, consensus EPS $-1.21 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • High volatility — position sizing and stops matter more here.
- • Confirm liquidity, spreads, and your own thesis before acting.
RAPP questions
What is the MarketPicks AI signal for Rapport Therapeutics, Inc. stock (RAPP)?
As of Nov 1, 10:55 PM ET, the ensemble reads bearish on RAPP — bearish — 6 of 16 bots down, with 1 bull, 6 bear and 9 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest RAPP price on MarketPicks?
RAPP was $25.05 on the latest quote (Nov 1, 10:55 PM ET), +3.47% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for RAPP mean?
Scores run from 0 to 100, with 50 neutral. RAPP shows momentum 0/100, trend velocity 4/100 and volatility risk 100/100, with news sentiment at 50/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.